Michael Allen Pulsipher
· ProfessorUniversity of Utah · Hematology & Oncology
Active 1984–2026
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Michael Allen Pulsipher, MD, is the Division Chief of Pediatric Hematology at Intermountain Primary Children’s Hospital and Oncology, the Director of the Children’s and Adolescent Cancer Initiative at Huntsman Cancer Institute, and holds a Presidential Chair in Pediatric Oncology and Hematology at the University of Utah. His research interests include allogeneic transplantation and cell therapy for acute leukemias, especially ALL, where he is running national research trials aimed at testing haploidentical approaches and assessing the role of NGS-MRD in identifying patients able to undergo less intensive BMT approaches. Dr. Pulsipher’s work in cell therapy contributed to the FDA approval of the first CART cell treatment, tisagenlecleucel, and he continues to run trials in CAR T, NK, and Viral Specific T-cell therapies. He has also done extensive work in reduced toxicity approaches to transplantation for both malignant and non-malignant disorders, and has led national protocols for patients with immunodeficiencies, HLH, and bone marrow failure. Additionally, he has conducted large trials assessing the safety and quality of life of pediatric bone marrow donors and is currently leading a national trial on the psychological well-being of donor and recipient families during the transplant process.
Research topics
- Medicine
- Internal medicine
- Oncology
- Immunology
- Pediatrics
- Gastroenterology
Selected publications
Blood Advances · 2025-06-24 · 13 citations
articleOpen accessABSTRACT: Since the first approval of tisagenlecleucel in 2017, pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) may receive this CD19-directed chimeric antigen receptor T-cell therapy. We report real-world data from the Center for International Blood and Marrow Transplant Research (>2.5 years of follow-up). As of 4 May 2022, 768 patients with B-ALL had received tisagenlecleucel. Patients aged ≥18 and <18 years of age (including those <3 yea…
Blood · 2025-04-15 · 6 citations
articleOpen accessABSTRACT: This study reports outcomes of Pediatric Leukemia Adoptive Therapy 02 (PLAT-02), a phase 2 trial of SCRI-CAR19, a second-generation chimeric antigen receptor (CAR) T-cell product with FMC63 single-chain variable fragment and 4-1BB costimulation, in pediatric and young adult patients with B-cell acute lymphoblastic leukemia; and PLAT-03, a companion study evaluating exogenous CD19 antigen stimulation with serial infusions of T cells expressing truncated CD19, T-cell antigen-presenting c…
Blood Advances · 2025-09-03 · 5 citations
articleOpen accessABSTRACT: Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative option for patients with high-risk malignancies and nonmalignant disorders. Long-term survival depends on robust immune reconstitution (IR), which governs overall immune homeostasis and risks of infection, graft-versus-host disease, and relapse. However, despite its centrality to posttransplant outcomes, IR is not consistently monitored across transplant centers, limiting ability to generate meaningful, comparable,…
Transplantation and Cellular Therapy · 2025-04-04 · 3 citations
articleOpen accessBACKGROUND: Melphalan is often used as the backbone agent for conditioning prior to A/B-T-cell depleted (A/B-TCD) hematopoietic cell transplant (HCT) due to lower rates of organ toxicity compared to busulfan or total-body irradiation, albeit with significant mucosal injury. Traditional dosing based on body-surface-area (BSA) may result in non-optimal melphalan exposure among certain patient subsets. OBJECTIVES: As mucosal injury is linked to initiation of alloreactivity, we hypothesized that hig…
Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation
Blood · 2025-10-08 · 3 citations
articleOpen accessABSTRACT: Chronic graft-versus-host-disease (cGVHD) is the primary nonrelapse limitation to a successful hematopoietic cell transplantation and is largely treated as a single biological entity. We hypothesized that there exist different biological subtypes of cGVHD. Using the Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) network database, which is derived from the largest pediatric cGVHD cohort worldwide, we applied clustering analysis to subtype patients with cGVHD from the ABLE…
Recent grants
NIH · $8.5M · 2017–2024
NIH · $839k · 2017
NIH · $1.3M · 2001–2024
Frequent coauthors
- 690 shared
Brenda M. Sandmaier
Fred Hutch Cancer Center
- 673 shared
Rainer Storb
University of Washington
- 659 shared
David G. Maloney
University of Washington
- 648 shared
Thomas R. Chauncey
Fred Hutch Cancer Center
- 635 shared
Barry E. Storer
- 588 shared
Michael B. Maris
Sarah Cannon
- 438 shared
Edward Agura
- 429 shared
Richard T. Maziarz
Oregon Health & Science University
Labs
Pediatric Hematology & Oncology at Primary Children's Hospital and Huntsman Cancer InstitutePI
Education
- 1996
Fellowship, Pediatric Hematology/Oncology
Dana Farber Cancer Institute
- 1993
Pediatric Residency, Pediatrics
Children's Hospital of Philadelphia
Awards & honors
- PTCTC Lifetime Achievement Award in 2020
Similar researchers at University of Utah
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Michael Allen Pulsipher
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup